Loading
Part of the B-cell receptor found on nearly all B-cell lymphomas; the target of the ADC polatuzumab vedotin and a frequently mutated gene in brain and testicular lymphoma. This dossier gathers the 1 product (1 approved), 8 trials, 0 pathways and 2 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Transmembrane Ig-superfamily protein with an ITAM motif; together with CD79a it couples antigen binding to SYK/BTK/PI3K signalling and mediates BCR internalisation.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Diffuse large B-cell lymphoma | 95% | surface expression | doi.org | |
| Primary CNS lymphoma | 50-70% | CD79B mutation |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
| Modality | Approved |
|---|---|
| ADC 1 |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
POLARGO NCT04182204 | 3 | Positive | Relapsed or refractory diffuse large B-cell lymphoma not eligible for an autologous transplant: polatuzumab vedotin added to rituximab, gemcitabine and oxaliplatin | Median overall survival 19.5 against 12.5 months (hazard ratio 0.6, p = 0.0017), with more peripheral neuropathy and more fatal infections. | |
SUNMO NCT05171647 | 3 | Positive | R/R LBCL, transplant-ineligible: mosunetuzumab + polatuzumab vs R-GemOx | PFS improved (HR reported 2025). | |
POLARIX NCT03274492 | 3 | Positive | Untreated DLBCL, IPI 2-5, age 18-80: Pola-R-CHP vs R-CHOP | 2-year PFS 76.7% vs 70.2%, HR 0.73; 5-year OS HR 0.85 (NS). | |
POLAR BEAR NCT04332822 | 3 | Active | Aged 80 or over, or 75 or over and frail, with untreated diffuse large B-cell lymphoma: R-miniCHOP against R-pola-miniCHP, which replaces the vincristine with polatuzumab vedotin | - | |
| 2 | Recruiting | A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL) | - | ||
| 2 | Recruiting | A Pivotal Phase II Randomised, Multi-centre, Open-label Study to Evaluate the Efficacy and Safety of MB-CART2019.1 Compared to SoC Therapy in Participants With r/r DLBCL, Who Are Not Eligible for HDC and ASCT | - | ||
| 1/2 | Active | An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma | - | ||
| 1/2 | Active | An Open-Label, Multi-Center, Phase IB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin (Plus a Single Pre-Treatment Dose of Obinutuzumab) in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | - |
Transcriptional down-regulation of MS4A1 rather than deletion: CD20 messenger RNA is lower in the negative cells than in the positive cells from the same patient.
The CD20 arm fails for the same reasons rituximab does: transcriptional down-regulation and shaving.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"CD79b" OR ABSTRACT:"CD79b" OR TITLE:"CD79B" OR ABSTRACT:"CD79B") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CD79b, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/cd79b.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/cd79b.json. Licence CC BY-NC 4.0.